78 related articles for article (PubMed ID: 22997961)
1. Hemangioblastic characteristics of cancer stem cells in chronic myeloid leukemia.
Xishan Z; Xu Z; Lawei Y; Gang L
Clin Lab; 2012; 58(7-8):607-13. PubMed ID: 22997961
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase-9 was involved in the immuno-modulatory defect of mesenchymal stem cell from chronic myeloid leukemia patients.
Zhu XS; Shi W; An GY; Zhang HM; Song YG; Li YB
Chin Med J (Engl); 2011 Aug; 124(16):2423-30. PubMed ID: 21933581
[TBL] [Abstract][Full Text] [Related]
3. TGF-beta1-induced PI3K/Akt/NF-kappaB/MMP9 signalling pathway is activated in Philadelphia chromosome-positive chronic myeloid leukaemia hemangioblasts.
Zhu X; Wang L; Zhang B; Li J; Dou X; Zhao RC
J Biochem; 2011 Apr; 149(4):405-14. PubMed ID: 21288887
[TBL] [Abstract][Full Text] [Related]
4. ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors.
Sun B; Jiang G; Zaydan MA; La Russa VF; Safah H; Ehrlich M
Cancer Res; 2001 Sep; 61(18):6931-7. PubMed ID: 11559572
[TBL] [Abstract][Full Text] [Related]
5. Absence of bcr/abl gene in single hemopoietic progenitors in some patients with chronic myelogenous leukemia.
Misawa M; Maeda H; Hara H; Yamamoto Y; Furuyama J
Stem Cells; 1993 Nov; 11(6):536-42. PubMed ID: 7509222
[TBL] [Abstract][Full Text] [Related]
6. Chronic myeloid leukemia stem cells.
Jamieson CH
Hematology Am Soc Hematol Educ Program; 2008; ():436-42. PubMed ID: 19074122
[TBL] [Abstract][Full Text] [Related]
7. Severe functional alterations in vitro in CD34(+) cell subpopulations from patients with chronic myeloid leukemia.
Chávez-González A; Rosas-Cabral A; Vela-Ojeda J; González JC; Mayani H
Leuk Res; 2004 Jun; 28(6):639-47. PubMed ID: 15120942
[TBL] [Abstract][Full Text] [Related]
8. The chronic myeloid leukemia stem cell.
Nicholson E; Holyoake T
Clin Lymphoma Myeloma; 2009; 9 Suppl 4():S376-81. PubMed ID: 20007106
[TBL] [Abstract][Full Text] [Related]
9. Impaired immunomodulatory function of chronic myeloid leukemia cancer stem cells and the possible mechanism involved in it.
Xishan Z; Xinna Z; Baoxin H; Jun R
Cancer Immunol Immunother; 2013 Apr; 62(4):689-703. PubMed ID: 23180012
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow derived mesenchymal stem cells from chronic myeloid leukemia t(9;22) patients are devoid of Philadelphia chromosome and support cord blood stem cell expansion.
Jootar S; Pornprasertsud N; Petvises S; Rerkamnuaychoke B; Disthabanchong S; Pakakasama S; Ungkanont A; Hongeng S
Leuk Res; 2006 Dec; 30(12):1493-8. PubMed ID: 16839603
[TBL] [Abstract][Full Text] [Related]
11. BCR/ABL-negative clonogenic hematopoietic cells do not accumulate in the plastic-adherent fraction of peripheral blood mononuclear cells from patients with chronic myeloid leukemia in stable chronic phase.
Schultheis B; Pasternak G; Hehlmann R
Folia Biol (Praha); 2000; 46(6):256-63. PubMed ID: 11140859
[TBL] [Abstract][Full Text] [Related]
12. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
Jiang X; Saw KM; Eaves A; Eaves C
J Natl Cancer Inst; 2007 May; 99(9):680-93. PubMed ID: 17470736
[TBL] [Abstract][Full Text] [Related]
13. Mobilization of hematopoietic progenitors in patients with chronic myeloid leukemia.
Thijsen SF; Schuurhuis GJ; van Oostveen JW; Theijsmeijer AP; Niewint AW; Ossenkoppele GJ
Bone Marrow Transplant; 1997 Nov; 20(10):835-42. PubMed ID: 9404923
[TBL] [Abstract][Full Text] [Related]
14. [Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation].
Qin YZ; Li JL; Zhu HH; Ruan GR; Li LD; Zhang Y; Xu LP; Liu DH; Liu YR; Huang XJ; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 Aug; 27(8):511-4. PubMed ID: 17172121
[TBL] [Abstract][Full Text] [Related]
15. The research on the immuno-modulatory defect of mesenchymal stem cell from Chronic Myeloid Leukemia patients.
Xishan Z; Guangyu A; Yuguang S; Hongmei Z
J Exp Clin Cancer Res; 2011 May; 30(1):47. PubMed ID: 21535879
[TBL] [Abstract][Full Text] [Related]
16. Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia.
Primo D; Flores J; Quijano S; Sanchez ML; Sarasquete ME; del Pino-Montes J; Gaarder PI; Gonzalez M; Orfao A
Br J Haematol; 2006 Oct; 135(1):43-51. PubMed ID: 16939497
[TBL] [Abstract][Full Text] [Related]
17. Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells.
Coppo P; Dusanter-Fourt I; Millot G; Nogueira MM; Dugray A; Bonnet ML; Mitjavila-Garcia MT; Le Pesteur D; Guilhot F; Vainchenker W; Sainteny F; Turhan AG
Oncogene; 2003 Jun; 22(26):4102-10. PubMed ID: 12821944
[TBL] [Abstract][Full Text] [Related]
18. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
19. Differential manipulation of normal and chronic myeloid leukemia stem cell proliferation in vitro.
Eaves C; Eaves A
Blood Cells; 1994; 20(1):83-93; discussion 93-5. PubMed ID: 7994064
[TBL] [Abstract][Full Text] [Related]
20. BCR/ABL oncogene-induced PI3K signaling pathway leads to chronic myeloid leukemia pathogenesis by impairing immuno-modulatory function of hemangioblasts.
Li Q; Wu Y; Fang S; Wang L; Qi H; Zhang Y; Zhang J; Li W
Cancer Gene Ther; 2015 May; 22(5):227-37. PubMed ID: 25837664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
